<?xml version='1.0' encoding='utf-8'?>
<section article="ghg" article_name="Health - General" number="13-4401" title_number="13" title_name="Miscellaneous Health Care Programs" subtitle_number="44" subtitle_name="Cannabis Use Baseline Study">
  <level label="a">
    <text>The Natalie M. LaPrade Medical Cannabis Commission, in consultation with the Department, the Behavioral Health Administration, the Governor’s Office of Crime Prevention and Policy, the Maryland Poison Center, the State’s designated Health Information Exchange, and the Maryland Hospital Association, shall conduct, or contract with an institution of higher education or a private research entity to conduct, a comprehensive baseline study of cannabis use in the State that includes a survey of:</text>
    <level label="1">
      <text>Patterns of use, including frequency of use and dosing, methods of consumption, and general perceptions of cannabis among:</text>
      <level label="i">
        <text>Individuals under the age of 18 years;</text>
      </level>
      <level label="ii">
        <text>Individuals at least 18 years old and under the age of 21 years;</text>
      </level>
      <level label="iii">
        <text>Individuals at least 21 years old and under the age of 55 years;</text>
      </level>
      <level label="iv">
        <text>Individuals at least 55 years old;</text>
      </level>
      <level label="v">
        <text>Pregnant women; and</text>
      </level>
      <level label="vi">
        <text>Breastfeeding women;</text>
      </level>
    </level>
    <level label="2">
      <text>Incidents of impaired driving, including arrests, accidents, and fatalities, related to cannabis use;</text>
    </level>
    <level label="3">
      <text>Hospitalizations related to cannabis use;</text>
    </level>
    <level label="4">
      <text>Calls to poison control centers related to cannabis use, including data on calls related to individuals under the age of 21 years; and</text>
    </level>
    <level label="5">
      <text>Diagnoses of cannabis use disorder and problem cannabis use.</text>
    </level>
  </level>
  <level label="b">
    <text>On or before March 1, 2023, the Natalie M. LaPrade Medical Cannabis Commission shall submit a report of the findings of the baseline study conducted under subsection (a) of this section to the Governor and, in accordance with § 2–1257 of the State Government Article, the Senate Finance Committee, the Senate Judicial Proceedings Committee, the House Judiciary Committee, and the House Health and Government Operations Committee.</text>
  </level>
  <level label="c">
    <text>On or before March 1, 2025, and every other year thereafter, the Natalie M. LaPrade Medical Cannabis Commission shall:</text>
    <level label="1">
      <text>Survey the same factors that are set forth in subsection (a) of this section;</text>
    </level>
    <level label="2">
      <text>Use the same methodology or model that is used to conduct the survey required under subsection (a) of this section; and</text>
    </level>
    <level label="3">
      <text>Submit a report of the findings of the survey required under this subsection to the Governor and, in accordance with § 2–1257 of the State Government Article, the Senate Finance Committee, the Senate Judicial Proceedings Committee, the House Judiciary Committee, and the House Health and Government Operations Committee.</text>
    </level>
  </level>
</section>
